Sermorelin is not established in the sources reviewed here as a reliable treatment for low libido, erectile dysfunction, or infertility. These are also different concerns. A person can have normal desire but difficulty with erections, or satisfactory sexual function but a fertility problem.
Start by telling the clinician what has changed and what outcome you want help with. A broad promise to optimize hormones can obscure the actual question. An improvement in energy or a hormone result should not be treated as proof that all aspects of sexual or reproductive health have improved.
A change in energy, testosterone, or IGF-1 does not by itself demonstrate improved sexual function or fertility. Define the concern before choosing treatment.
Desire, erections, and fertility need different measures
Libido describes sexual interest or desire. Erectile function concerns obtaining or maintaining an erection. Fertility concerns the ability to achieve pregnancy in the relevant clinical context. These outcomes can overlap without becoming interchangeable.
The NIDDK's erectile dysfunction overview defines ED as a specific sexual-function problem that can warrant medical assessment. It is not diagnosed from an IGF-1 result or solved by assuming more growth-hormone signaling is needed. Describe the symptom directly, even if a clinic's intake form uses broader wording.
A testosterone question requires a testosterone assessment
The Endocrine Society testosterone guideline requires compatible symptoms and consistently low, appropriately measured testosterone for diagnosis of hypogonadism in men. Feeling less interested in sex does not by itself establish that diagnosis, and a peptide's effect on another hormone does not substitute for the evaluation.
Our men's health guide explains why sermorelin is not testosterone replacement. Ask the clinician to consider the full context, including medicines, existing medical conditions, sleep, and changes in wellbeing, rather than selecting a treatment solely from the symptom's appearance in an advertisement.
Fertility goals belong in the first conversation
Tell the clinician if you are trying to conceive now or may want to in the future. The AUA/ASRM male infertility guideline advises against prescribing exogenous testosterone to men interested in current or future fertility. The assessment may involve reproductive history, examination, semen testing, and other directed evaluation.
Adding sermorelin should not be represented as a proven way to preserve fertility during testosterone treatment. The TRT guide discusses why each additional prescription needs its own rationale. Ask whether a reproductive specialist should be involved before a hormone plan is changed.
What about enclomiphene combinations?
Enclomiphene and sermorelin are different drugs. Findings about testosterone or sperm counts in selected enclomiphene studies do not establish pregnancy benefit from a sermorelin combination. Nor do they establish that the same treatment fits every cause of a fertility problem.
Read sermorelin versus enclomiphene for the study context and limitations. Ask the clinician to distinguish a laboratory change, a symptom improvement, and a reproductive outcome when describing the expected benefit.
Women's concerns also deserve a focused assessment
Questions about reduced desire, discomfort, menopausal symptoms, or difficulty conceiving should not be reduced to a generic recommendation for a growth-related peptide. Describe which issue is present and whether there are associated symptoms. The guide for women discusses why the marketing category of hormone optimization is broader than a diagnosis.
If pregnancy is possible or planned, disclose that before considering treatment. Do not infer reproductive safety from research in older adults or from another person's successful pregnancy story. The appropriate evidence has to address the population and treatment being considered.
Agree on an outcome that matches the concern
Ask what assessment is needed, which treatment options have evidence for the actual problem, how progress will be measured, and when to seek follow-up. Keep a record of medication changes and symptoms so the next appointment can evaluate a concrete pattern.
Our appointment checklist can help prepare the discussion. A worthwhile care plan should answer your sexual or reproductive concern directly; it should not use a higher hormone number as a substitute for an outcome that matters to you.
Sources & further reading
Provider pages describe offers; they do not independently establish treatment benefits. Sources checked September 20, 2026.
This article is education, not a diagnosis, prescription, or dosing plan. Discuss treatment and alternatives with a licensed clinician who knows your history. Compounded medications are not FDA-approved.